| Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor AM van der Sloot, V Tur, E Szegezdi, MM Mullally, RH Cool, A Samali, ... Proceedings of the National Academy of Sciences 103 (23), 8634-8639, 2006 | 218 | 2006 |
| Computational design of peptide ligands P Vanhee, AM van der Sloot, E Verschueren, L Serrano, F Rousseau, ... Trends in biotechnology 29 (5), 231-239, 2011 | 191 | 2011 |
| RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line–derived neurotrophic factor I Plaza Menacho, R Koster, AM van der Sloot, WJ Quax, J Osinga, ... Cancer research 65 (5), 1729-1737, 2005 | 110 | 2005 |
| Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants CR Reis, AM Van Der Sloot, A Natoni, E Szegezdi, R Setroikromo, ... Cell death & disease 1 (10), e83-e83, 2010 | 100 | 2010 |
| DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design V Tur, AM van der Sloot, CR Reis, E Szegezdi, RH Cool, A Samali, ... Journal of Biological Chemistry 283 (29), 20560-20568, 2008 | 84 | 2008 |
| Engineering of weak helper interactions for high-efficiency FRET probes R Grünberg, JV Burnier, T Ferrar, V Beltran-Sastre, F Stricher, ... Nature methods 10 (10), 1021-1027, 2013 | 83 | 2013 |
| A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome JEH Bergman, N Janssen, AM van der Sloot, HEK de Walle, J Schoots, ... Human mutation 33 (8), 1251-1260, 2012 | 82 | 2012 |
| A Novel Genetic Selection System for Improved Enantioselectivity of Bacillus subtilis Lipase A YL Boersma, MJ Dröge, AM van der Sloot, T Pijning, RH Cool, ... ChemBioChem 9 (7), 1110-1115, 2008 | 82 | 2008 |
| Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity L O'Leary, AM van der Sloot, CR Reis, S Deegan, AE Ryan, SPS Dhami, ... Oncogene 35 (10), 1261-1270, 2016 | 77 | 2016 |
| Stabilization of TRAIL, an all-β-sheet multimeric protein, using computational redesign AM van der Sloot, MM Mullally, G Fernandez-Ballester, L Serrano, ... Protein Engineering Design and Selection 17 (9), 673-680, 2004 | 50 | 2004 |
| Imipridone anticancer compounds ectopically activate the ClpP protease and represent a new scaffold for antibiotic development S Jacques, AM van der Sloot, C C. Huard, J Coulombe-Huntington, ... Genetics 214 (4), 1103-1120, 2020 | 49 | 2020 |
| Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants C Xu, D Cassatella, AM van der Sloot, R Quinton, M Hauschild, ... Genetics in medicine 20 (8), 872-881, 2018 | 49 | 2018 |
| Loop grafting of Bacillus subtilis lipase A: inversion of enantioselectivity YL Boersma, T Pijning, MS Bosma, AM van der Sloot, LF Godinho, ... Chemistry & biology 15 (8), 782-789, 2008 | 49 | 2008 |
| An improved understanding of TNFL/TNFR interactions using structure-based classifications C Magis, AM van der Sloot, L Serrano, C Notredame Trends in biochemical sciences 37 (9), 353-363, 2012 | 47 | 2012 |
| Building blocks for protein interaction devices R Grünberg, TS Ferrar, AM van der Sloot, M Constante, L Serrano Nucleic acids research 38 (8), 2645-2662, 2010 | 46 | 2010 |
| Binding of phage displayed Bacillus subtilis lipase A to a phosphonate suicide inhibitor MJ Dröge, CJ Rüggeberg, AM van der Sloot, J Schimmel, DS Dijkstra, ... Journal of biotechnology 101 (1), 19-28, 2003 | 44 | 2003 |
| Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors CR Reis, AM van der Sloot, E Szegezdi, A Natoni, V Tur, RH Cool, ... Biochemistry 48 (10), 2180-2191, 2009 | 42 | 2009 |
| Protein design with fragment databases E Verschueren, P Vanhee, AM Van Der Sloot, L Serrano, F Rousseau, ... Current opinion in structural biology 21 (4), 452-459, 2011 | 40 | 2011 |
| Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL E Szegezdi, AM Van Der Sloot, D Mahalingam, L O'Leary, RH Cool, ... Molecular & Cellular Proteomics 11 (3), 2012 | 33 | 2012 |
| Targeting AML through DR4 with a novel variant of rhTRAIL E Szegezdi, CR Reis, AM Sloot, A Natoni, A O’Reilly, J Reeve, RH Cool, ... Journal of cellular and molecular medicine 15 (10), 2216-2231, 2011 | 33 | 2011 |
Wim J. QuaxProfessor of Pharmaceutical Biology在 rug.nl 的电子邮件经过验证
